AstraZeneca Pharma India reports 37% second-quarter revenue growth

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.3%Reaction day

₹9012.00

prior close

₹9201.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%+0.7% vs market

Pharmaceuticals peers, median of 155sector-0.1%+0.4% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty Microcap 250 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-1.7

15m

-2.0

30m

-3.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.3-0.4+0.7-0.1+0.4

Next day

+1.3-0.6+2.0-0.8+2.1

+2.8+0.3+2.5+0.2+2.6

+2.0+0.2+1.8-0.0+2.0

+1.7+0.1+1.6+0.2+1.5

+1.4+0.7+0.7+0.3+1.1

+0.8-0.3+1.1-0.9+1.6

15d

+0.3-2.0+2.3-1.5+1.7

-0.4-5.7+5.2-3.8+3.4

-9.4-7.8-1.6-6.2-3.2

-0.1-4.6+4.5-6.9+6.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

AstraZeneca Pharma India reported unaudited second-quarter revenue of INR 5,590.9 million, up 37% from INR 4,080.0 million a year earlier. Profit after the exceptional item and tax was INR 542.2 million, compared with INR 384.3 million. First-half revenue reached INR 10,854.0 million, and seven new approvals supported growth, led by cancer medicines.

Likely market impact

Strong revenue and profit growth may support the stock, but investors should review the exceptional item and unaudited numbers.